Literature DB >> 33237291

Clinical, Laboratory, and Interferon-Alpha Response Characteristics of Patients With Chilblain-like Lesions During the COVID-19 Pandemic.

Thomas Hubiche1, Nathalie Cardot-Leccia2, Florence Le Duff1, Barbara Seitz-Polski3, Pascal Giordana4, Christine Chiaverini1, Valérie Giordanengo5,6, Géraldine Gonfrier5, Vincent Raimondi7, Olivier Bausset7, Zoubir Adjtoutah7, Margaux Garnier1, Fanny Burel-Vandenbos2, Bérengère Dadone-Montaudié2,8,9, Véréna Fassbender4, Aurélia Palladini1, Johan Courjon10, Véronique Mondain10, Julie Contenti11, Jean Dellamonica12, Georges Leftheriotis4, Thierry Passeron1,6.   

Abstract

Importance: Chilblain-like lesions have been reported during the coronavirus 2019 (COVID-19) pandemic. The pathophysiology of such manifestations remains largely unknown. Objective: To perform a systematic clinical, histologic, and biologic assessment in a cohort of patients with chilblain-like lesions occurring during the COVID-19 pandemic. Design, Setting, and Participants: In this prospective case series carried out with a COVID-19 multidisciplinary consultation group at the University Hospital of Nice, France, 40 consecutive patients presenting with chilblain-like lesions were included. Main Outcomes and Measures: Patients underwent a thorough general and dermatologic examination, including skin biopsies, vascular investigations, biologic analyses, interferon-alpha (IFN-α) stimulation and detection, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) polymerase chain reaction (PCR) and serologic analysis.
Results: Overall, 40 consecutive patients with chilblain-like lesions were included. Most patients were young, with a median (range) age of 22 (12-67) years; 19 were male and 21 were female. The clinical presentation was highly reproducible with chilblain-like lesions mostly on the toes. Bullous and necrotic evolution was observed in 11 patients. Acrocyanosis or cold toes were reported in 19 (47.5%) cases. Criteria compatible with COVID-19 cases were noted in 11 (27.5%) within 6 weeks prior to the eruption. The real-time PCR (rt-PCR) testing results were negative in all cases. Overall, SARS-CoV-2 serology results were positive in 12 patients (30%). D-dimer concentration levels were elevated in 24 (60.0%) cases. Cryoglobulinemia and parvovirus B19 serologic results were negative for all tested patients. The major histologic findings were features of lymphocytic inflammation and vascular damage with thickening of venule walls and pericyte hyperplasia. A significant increase of IFN-α production after in vitro stimulation was observed in the chilblain population compared with patients with mild-severe acute COVID-19. Conclusions and Relevance: Taken together, our results suggest that chilblain-like lesions observed during the COVID-19 pandemic represent manifestations of a viral-induced type I interferonopathy. Trial Registration: ClinicalTrials.gov Identifier: NCT04344119.

Entities:  

Year:  2021        PMID: 33237291      PMCID: PMC7689569          DOI: 10.1001/jamadermatol.2020.4324

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN: 2168-6068            Impact factor:   10.282


  41 in total

1.  Are 'COVID toes' actually caused by the coronavirus?

Authors:  Cassandra Willyard
Journal:  Nature       Date:  2022-03       Impact factor: 49.962

2.  Type I Interferon Signature in Chilblains Following SARS-CoV-2 mRNA Vaccine: A Case Report.

Authors:  Karim Souaid; Bénédicte Oulès; Pierre Sohier; Lydia Deschamps; Sélim Aractingi; Nicolas Dupin
Journal:  Acta Derm Venereol       Date:  2021-11-10       Impact factor: 3.875

3.  Long-term Outcome of Chilblains Associated with SARS-CoV-2.

Authors:  Florence Poizeau; Sébastien Barbarot; Yannick Le Corre; Emilie Brenaut; Mahtab Samimi; Hélène Aubert; Alexis Toubel; Alain Dupuy
Journal:  Acta Derm Venereol       Date:  2021-12-13       Impact factor: 3.875

4.  BNT162b2 mRNA COVID-19 vaccine-induced chilblain-like lesions reinforces the hypothesis of their relationship with SARS-CoV-2.

Authors:  V Piccolo; A Bassi; G Argenziano; C Mazzatenta; M Cutrone; I Neri; R Grimalt; T Russo
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-05-10       Impact factor: 9.228

5.  Frequency of relapse and persistent cutaneous symptoms after a first episode of chilblain-like lesion during the COVID-19 pandemic.

Authors:  P Moghadam; L Frumholtz; L Jaume; A De Masson; M Jachiet; E Begon; L Sulimovic; A Petit; H Bachelez; M Bagot; J-D Bouaziz; C Cassius
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-06-19       Impact factor: 9.228

6.  Contemporary occurrence of Chilblain-like lesions and Pityriasis rosea during the COVID-19 pandemic.

Authors:  V Piccolo; A Bassi; G Argenziano; C Mazzatenta; M Cutrone; I Neri; R Grimalt; T Russo
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-06-07       Impact factor: 9.228

7.  Pernio after COVID-19 vaccination.

Authors:  S Lopez; P Vakharia; T Vandergriff; E E Freeman; R Vasquez
Journal:  Br J Dermatol       Date:  2021-05-31       Impact factor: 11.113

8.  Long-Term Persistence of Anti-SARS-CoV-2 Antibodies in a Pediatric Population.

Authors:  Ana Méndez-Echevarría; Talía Sainz; Iker Falces-Romero; Beatriz de Felipe; Lucia Escolano; Sonia Alcolea; Lidia Pertiñez; Olaf Neth; Cristina Calvo
Journal:  Pathogens       Date:  2021-06-04

9.  Purpuric lesions on the eyelids developed after BNT162b2 mRNA COVID-19 vaccine: another piece of SARS-CoV-2 skin puzzle?

Authors:  C Mazzatenta; V Piccolo; G Pace; I Romano; G Argenziano; A Bassi
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-05-28       Impact factor: 9.228

10.  Prognosis of rash and chilblain-like lesions among outpatients with COVID-19: a large cohort study.

Authors:  Hélène Mascitti; Patrick Jourdain; Alexandre Bleibtreu; Luc Jaulmes; Agnès Dechartres; Xavier Lescure; Youri Yordanov; Aurélien Dinh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-07-13       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.